BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids derived from a protective protein found in human gastric juice. Since its discovery, it has become one of the most extensively studied regenerative peptides in preclinical research, with over 100 published studies spanning tissue repair, cytoprotection, and angiogenesis.
Molecular Profile
BPC-157 has a molecular weight of 1419.53 g/mol and the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its CAS number is 137525-51-0. Unlike many bioactive peptides, BPC-157 demonstrates remarkable stability in human gastric juice, maintaining its structure and biological activity even at low pH — a property that has driven research interest in oral bioavailability.
Key Mechanisms of Action
Growth Factor Modulation
Preclinical studies have demonstrated that BPC-157 upregulates several critical growth factors in tissue repair pathways:
- VEGF (Vascular Endothelial Growth Factor) — promotes angiogenesis and new blood vessel formation at injury sites
- EGF (Epidermal Growth Factor) — accelerates epithelial cell migration and proliferation
- FGF (Fibroblast Growth Factor) — stimulates fibroblast activity and collagen deposition
Nitric Oxide System
BPC-157 interacts with the nitric oxide (NO) system, which plays a central role in vascular function, inflammation, and tissue repair. Research suggests it may modulate both NOS (nitric oxide synthase) expression and NO pathway signaling, contributing to its observed effects on blood vessel formation and tissue healing.
Cytoprotective Properties
In rodent models, BPC-157 has shown cytoprotective effects across multiple organ systems:
- Gastrointestinal tract — protection against NSAID-induced lesions, alcohol-induced damage, and stress ulcers
- Hepatic tissue — reduced liver damage markers in hepatotoxicity models
- Musculoskeletal system — accelerated healing in tendon, ligament, and muscle injury models
Notable Preclinical Findings
Research has generated several significant findings across different injury and disease models:
- Rodent tendon-to-bone healing studies showed accelerated functional recovery and increased collagen organization at the repair site
- In vitro endothelial cell studies demonstrated dose-dependent promotion of tube formation (angiogenesis marker)
- GI tract studies showed protection against multiple damage models including cysteamine-induced duodenal ulcers
- Muscle injury models showed faster restoration of muscle function and reduced fibrosis compared to controls
Current Research Directions
Active areas of BPC-157 investigation include:
- Oral vs. injectable administration — comparative bioavailability and efficacy studies
- Combination protocols — synergistic effects with other regenerative peptides such as TB-500
- Dose-response characterization — establishing optimal concentration ranges for different tissue types
- Mechanism elucidation — detailed mapping of downstream signaling cascades
Summary
BPC-157 remains one of the most actively studied peptides in regenerative research due to its multi-system cytoprotective profile, growth factor modulation, and unique gastric juice stability. Its broad preclinical evidence base makes it a valuable tool for researchers investigating tissue repair, angiogenesis, and protective mechanisms.
All information presented is based on published preclinical research. BPC-157 is sold for laboratory and research use only.
Disclaimer: This article is provided for educational and informational purposes only. All products referenced are intended strictly for laboratory and research use.
